Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Average Rating of "Buy" from Brokerages
Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) have earned an average rating of "Buy" from the ten research firms that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, seven have given a buy recommendation...